fda glp-1 warning letters september 2025 issued 30 to telehealth companies for false and misleading claims about compounded products. This marks the second round of enforcement action since the agency's crackdown on misleading FDA Targets GLP-1 and Peptide

Providers may benefit from: Clear prescription workflows Transparent communication Educational support resources Ongoing coordination aligned with compliance standards Choosing the right partner helps practices deliver better patient experiences and maintain confidence in therapy programs

[DOI] [PMC free article] [PubMed] [Google Scholar] 10.Yaribeygi H., Sathyapalan T., Sahebkar A

Mediators of Inflammation in Polycystic Ovary Syndrome in Relation to Adiposity

10.1056/NEJMoa1509225 [DOI] [PubMed] [Google Scholar] 11.Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, et al

Patients taking naltrexone regularly report that drinking feels less pleasurable